WellSpan officials celebrate progress in construction of 3 WellSpan hospitals
When opened, WellSpan Carlisle Hospital, WellSpan Newberry Hospital and WellSpan Shrewsbury Hospital will provide a new approach to care in the region, using a smaller format structure that streamlines efficiencies.
Each hospital, which is expected to open in early 2026, will feature:
'Patients requiring hospital-level care will benefit from this nationally proven model that touts emergency department wait times of less than 10 minutes as well as diagnostic results averaging around 20 minutes,' explained Daniel Hernandez, vice president of WellSpan's neighborhood hospitals. 'I'm so excited to be a part of the team that is introducing a proven and innovative model of care to the region.'
The hospital emergency departments will treat common emergency care needs such as falls, injuries, burns and infections. All three of the new hospitals will be fully licensed and offer high-quality patient services, in alignment with the quality provided at other WellSpan locations.
'It has taken several groups working together as one team to envision, plan and construct these new facilities to better serve our communities and we celebrate the efforts of everyone involved,' said Victoria Diamond, senior vice president of WellSpan's central region. 'The excitement of seeing such significant progress adds a renewed energy to the projects as we continue pushing forward to our early 2026 opening of these hospitals.'
The Carlisle hospital in Cumberland County will be located at the corner of Sprint Drive and Walnut Bottom Road in South Middleton Township, in the center of one of the fastest-growing counties in Pennsylvania.
The Newberry and Shrewsbury hospitals will be located in York County, both just off exits of busy Interstate 83. WellSpan Newberry Hospital will be located at 36 Robinhood Drive in Newberry Township, adjacent to a number of businesses and growing residential areas. And WellSpan Shrewsbury Hospital will be located at 13515 Wolfe Road in New Freedom.
For details on WellSpan's other nine acute care hospitals across central Pennsylvania, visit www.WellSpan.org/Hospitals.
Attachments
Ryan Coyle WellSpan Health 7178513151 [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
2 hours ago
- Washington Post
The worst way to achieve herd immunity is demonizing anti-vaxxers
Monica Hesse described in her July 15 op-ed, 'There's no vaccine for this,' her dismay at the state of U.S. measles vaccination rates. She fears that the loss of herd immunity will harm those who aren't able to be vaccinated, but wrote that 'what makes me worry most is that the people causing the collapse in herd immunity do not seem to understand that.' That framing reveals an unfortunately common lack of understanding of those 'causing the collapse.'
Yahoo
2 hours ago
- Yahoo
This High-Yield Dividend Stock Is Staging a Comeback. Should You Buy Shares Now?
When a 'boring' healthcare stock posts a 7% surge intraday, investors take notice. That's exactly what happened when CVS Health delivered its second-quarter 2025 earnings on July 31. The healthcare giant's adjusted earnings of $1.81 per share crushed analyst estimates of $1.45, while revenue climbed 8.4% year-over-year to $98.92 billion. This impressive beat comes at a time when the S&P 500 Healthcare Index ($SRHC) fell 12% over the past year, significantly trailing the broader S&P 500 Index's ($SPX) gain of 18.2%. CVS itself endured a particularly volatile 2024, cutting its earnings guidance three times and watching its stock plummet over 40% as medical costs in its Aetna insurance division spiraled higher than expected. More News from Barchart This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day? Worried About a Stock Market Crash? These Dividend Stocks Can Help You Ride It Out Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Yet, with its latest results stirring up fresh optimism, it's worth asking - is this high-yield dividend stock at the start of a legitimate comeback, or was the Q2 surprise - like last Thursday's intraday rally - just a fleeting moment of glory? Let's dive in. CVS's Latest Q2 Financial Results CVS Health (CVS), a retail pharmacy, healthcare services, and insurance company, boasts a market capitalization of approximately $79 billion. The company's high-yield credentials are anchored by a robust annual dividend rate of $2.66, delivering shareholders an above-market dividend yield of 4.26%, and elevating CVS into the upper echelon of dividend stocks. Shares have surged 37.1% year-to-date, but CVS stock trades at just 10.05x forward adjusted earnings - a generous discount to the healthcare sector median of 16.86x - and boasts a similarly low price/earnings-to-growth (PEG) ratio of only 0.59x. This lower multiple suggests the market still underappreciates CVS's earnings momentum and long-term growth prospects. In the July 31 Q2 report, total revenues climbed to $98.9 billion, marking an 8.4% year-over-year gain that eclipsed analysts' forecasts. While second-quarter GAAP diluted EPS landed at $0.80, down from $1.41 a year earlier, this was mainly due to two significant litigation charges tied to legacy business issues. Perhaps more importantly, management reported $6.5 billion in cash flow from operations year-to-date, reinforcing both dividend security and strategic agility. The company's earnings power is being driven by improved performances in its Health Care Benefits and Pharmacy & Consumer Wellness segments, offsetting short-term headwinds in Health Services. CVS's Next Strategic Act CVS inked a pivotal deal with Rite Aid, agreeing to acquire select prescription files and store locations across 15 states. This acquisition stands to significantly broaden CVS's market reach while promising meaningful operational synergies. This could be a crucial lever as CVS aims to build scale and streamline retail pharmacy operations at a time when consumer patterns are evolving fast. In another move to future-proof its business, CVS Health committed a staggering $20 billion investment over the next decade to overhaul healthcare delivery, with a focus on harnessing advanced technology and achieving real interoperability across its ecosystem. This is a long-term wager on connecting care in ways that competitors haven't matched. May 2025 brought another headline-worthy shift: CVS Caremark struck an exclusive partnership with Novo Nordisk (NVO), designating Wegovy as the preferred GLP-1 weight loss drug on all Caremark standard formularies starting July 1. This decision impacts tens of millions of Caremark beneficiaries and, at the same time, removes Eli Lilly's (LLY) Zepbound from CVS's standard list. CVS Pharmacy is now also the inaugural retail pharmacy in Novo's NovoCare network, offering the in-demand Wegovy at a sharply competitive $499 per month for cash-paying customers across all 9,000 CVS locations. Analysts' Consensus on CVS The average consensus among Wall Street analysts is strikingly bullish, forecasting earnings per share of $1.42 for the current quarter, up sharply from $1.09 a year ago, and $6.37 for the full fiscal year, compared to $5.42 last year. That's a growth rate estimate of +30.28% for the quarter and +17.53% for the year,. Backing up this optimism, CVS management hiked its outlook, boosting the full-year adjusted EPS guidance to a range of $6.30 to $6.40 from a prior $6.00 to $6.20. At the same time, the company expects at least $7.5 billion in operating cash flow, up from its earlier $7.0 billion forecast, and offered refined GAAP diluted EPS guidance between $3.84 and $3.94. Perhaps most compelling for prospective investors, nearly three-quarters of the 23 analysts in coverage rate CVS a 'Strong Buy.' The mean analyst price target is $79.41, pointing to a promising 29.2% upside potential from CVS's current price. Conclusion With the majority of analysts labeling CVS a 'Strong Buy' and nearly 30% upside baked into price targets, it's hard to ignore the opportunity here. CVS checks the boxes for value, growth, and high yield, all wrapped in a comeback narrative the market loves. At current levels, the stock could be a compelling value pick for yield hunters as its turnaround gains traction. However, given its placement across policy-sensitive sectors like healthcare and insurance, investors should be prepared for potential headline-driven volatility along with that passive income. On the date of publication, Ebube Jones did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
2 hours ago
- Yahoo
The disease which takes 3.5 years to diagnose after symptoms start
A disease that affects almost one million people in the UK takes around 3.5 years to diagnose, researchers have found. Dementia sufferers have to wait a lengthy time from the onset of symptoms to an official diagnosis. And some people with early-onset dementia have an even longer wait of just over four years. A new study by UCL researchers is the first systematic review and meta-analysis of global evidence examining time to diagnosis in dementia. READ MORE: Learner drivers 'struggling to pass' as three Midland test centres among the UK's toughest The researchers reviewed data from 13 previously published studies which took place in Europe, US, Australia and China, reporting data on 30,257 participants. The study, published in the International Journal of Geriatric Psychiatry, investigated the average interval between symptom onset rated by patients or family carers using interviews or medical records to the final diagnosis of dementia. Lead author, Dr Vasiliki Orgeta, said: "Timely diagnosis of dementia remains a major global challenge, shaped by a complex set of factors, and specific healthcare strategies are urgently needed to improve it. "Other studies estimate that only 50-65% of cases are ever diagnosed in high-income countries, with many countries having even lower diagnostic rates. 'Timely diagnosis can improve access to treatments and for some people prolong the time living with mild dementia before symptoms worsen.' In a pooled meta-analysis of 10 of the included studies, the researchers found that it typically takes 3.5 years from the first alert of symptoms to a patient receiving a diagnosis of dementia, or 4.1 years for those with early-onset dementia, with some groups more likely to experience longer delays, a spokesperson for UCL said. They found that younger age at onset and having frontotemporal dementia were both linked to longer time to diagnosis. While data on racial disparities was limited, one of the studies reviewed found that black patients tended to experience a longer delay before diagnosis. Dr Orgeta said: 'Our work highlights the need for a clear conceptual framework on time to diagnosis in dementia, developed in collaboration with people with dementia, their carers, and supporters.' Dr Phuong Leung (UCL Division of Psychiatry) said: 'Symptoms of dementia are often mistaken for normal ageing, while fear, stigma, and low public awareness can discourage people from seeking help.' Professor Rafael Del-Pino-Casado, of the University of Jaén, Spain, said: 'Within healthcare systems, inconsistent referral pathways, limited access to specialists, and under-resourced memory clinics can create further delays. For some, language differences or a lack of culturally appropriate assessment tools can make access to timely diagnosis even harder.' Dr Orgeta added: 'To speed up dementia diagnosis, we need action on multiple fronts. Public awareness campaigns can help improve understanding of early symptoms and reduce stigma, encouraging people to seek help sooner. "Clinician training is critical to improve early recognition and referral, along with access to early intervention and individualised support so that people with dementia and their families can get the help they need.' The NHS lists common early symptoms of dementia as: memory loss difficulty concentrating finding it hard to carry out familiar daily tasks, such as getting confused over the correct change when shopping struggling to follow a conversation or find the right word being confused about time and place mood changes
